Insulin

PIONEER TEENS phase 3a: first oral GLP‑1 RA trial in 10–17‑year-olds with type 2 diabetes (n=132). 52‑week, placebo‑controlled; safety matched adult trials; regulatory filings planned H2.

Petrelintide shows significant weight loss and good tolerability in Phase II trial, supporting further development for chronic weight management.

Investing €200M, the company will build a fully automated cold warehouse and a multi-purpose building for medical tech, creating 500 jobs and expanding insulin production capabilities.

The new plant, costing EUR 30 million, will produce monoclonal antibodies for trials, doubling production capacity and enhancing the company's biopharmaceutical focus and market position.